HER2DX®
HER2-positive Breast Cancer
CommercialActive
Key Facts
About Reveal Genomics
Reveal Genomics is a private, commercial-stage diagnostics company focused on redefining precision oncology through integrated genomic and clinical data analysis. The company has successfully launched HER2DX®, its first proprietary test for HER2+ breast cancer treatment stratification, positioning it as a revenue-generating entity. Backed by a strong scientific founding team and public grant funding from Spanish and EU programs, Reveal Genomics is building a platform to develop further complex, interpretable diagnostic tests. Its near-term strategy involves commercial expansion of HER2DX® and leveraging its platform for new assay development.
View full company profileTherapeutic Areas
Other HER2-positive Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Anbenitamab (KN026) | AlphaMab Oncology | Phase 3 |
| Membrex™ | Metaclipse Therapeutics | Pre-clinical |
| HER2+ cVLP Vaccine | AdaptVac | Phase 1 |
| NERLYNX® (neratinib) | Specialized Therapeutics | Commercial |
| Undisclosed Enhanced Antibody Program | Score Pharma | Pre-clinical |